Publications

Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies.

Date Published: January 1, 2021
Human tuberculosis (TB) is primarily caused by Mycobacterium tuberculosis (Mtb) that inhabits inside and amidst immune cells of the host with adapted physiology to regulate interdependent cellular functions with intact pathogenic potential. The complexity of this disease is attributed to various factors such as the reactivation of latent TB form…

Current advances in the clinical development of anti-tubercular agents.

Date Published: December 5, 2020
Tuberculosis (TB) is a communicable airborne infectious disease caused by the Mycobacterium tuberculosis (MTB) that primarily affects the lungs, and can disseminate to other parts of the body. MTB is one of the most dangerous pathogens, killing about 1.4 million people annually worldwide. Although the standard treatment of TB is…

Tissue specific diversification, virulence and immune response to BCG in a patient with an IFN-γ R1 deficiency.

Date Published: December 1, 2020
: We characterized BCG isolates found in lung and brain samples from a previously vaccinated patient with IFNγR1 deficiency. The isolates collected displayed distinct genomic and phenotypic features consistent with host adaptation and associated changes in antibiotic susceptibility and virulence traits. : We report a case of a patient with…

6,11-Dioxobenzo[]pyrido[1,2-]indoles Kill by Targeting Iron-Sulfur Protein Rv0338c (IspQ), A Putative Redox Sensor.

Date Published: November 13, 2020
Screening of a diversity-oriented compound library led to the identification of two 6,11-dioxobenzo[]pyrido[1,2-]indoles (DBPI) that displayed low micromolar bactericidal activity against the Erdman strain of . The activity of these hit compounds was limited to tubercle bacilli, including the nonreplicating form, and to . On hit expansion and investigation of…

Design, synthesis, in silico and in vitro evaluation of novel diphenyl ether derivatives as potential antitubercular agents.

Date Published: November 10, 2020
Diphenyl ether derivatives inhibit mycobacterial cell wall synthesis by inhibiting an enzyme, enoyl-acyl carrier protein reductase (InhA), which catalyses the last step in the fatty acid synthesis cycle of genus Mycobacterium. To select and validate a protein crystal structure of enoyl-acyl carrier protein reductase of Mycobacterium tuberculosis for designing inhibitors…

Urinary biomarkers of mycobacterial load and treatment response in pulmonary tuberculosis.

Date Published: September 17, 2020
BACKGROUNDControl of the tuberculosis (TB) pandemic remains hindered in part by a lack of simple and accurate measures of treatment efficacy, as current gold standard markers rely on sputum-based assays that are slow and challenging to implement. However, previous work identified urinary N1, N12-diacetylspermine (DiAcSpm), neopterin, hydroxykynurenine, N-acetylhexosamine, ureidopropionic acid,…

Increased Neutrophil Count and Decreased Neutrophil CD15 Expression Correlate With TB Disease Severity and Treatment Response Irrespective of HIV Co-infection.

Date Published: August 28, 2020
Tuberculosis remains a leading cause of death globally despite curative treatment, partly due to the difficulty of identifying patients who will not respond to therapy. Simple host biomarkers that correlate with response to drug treatment would facilitate improvement in outcomes and the evaluation of novel therapies. In a prospective longitudinal…
Courtesy of the U.S. National Library of Medicine